Chimeric Therapeutics Limited
CHMMF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $3 | $2 | $31 | $25 |
| - Cash | $6 | $5 | $3 | $4 |
| + Debt | $0 | $0 | $4 | $0 |
| Enterprise Value | -$3 | -$3 | $31 | $21 |
| Revenue | $7 | $6 | -$4 | $5 |
| % Growth | 28.4% | 258.1% | -164% | – |
| Gross Profit | $6 | $6 | -$4 | $11 |
| % Margin | 88.1% | 100% | 100% | 200% |
| EBITDA | -$3 | -$2 | -$13 | $2 |
| % Margin | -46% | -39.1% | 383.4% | 40.9% |
| Net Income | -$8 | -$3 | -$15 | $2 |
| % Margin | -106.2% | -51.5% | 426.3% | 44.6% |
| EPS Diluted | -0.005 | -0.003 | -0.022 | 0.004 |
| % Growth | -60.7% | 87.3% | -600% | – |
| Operating Cash Flow | -$5 | -$3 | -$3 | -$5 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$5 | -$3 | -$3 | -$5 |